Unaudited financial results (standalone and consolidated) for the Quarter ended 31st December 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indrayani Biotech reported Q3 FY26 standalone revenue of Rs. 520.10 lakhs, down about 36% from Rs. 818.82 lakhs a year ago, with standalone net profit of just Rs. 8.02 lakhs (vs Rs. 10.61 lakhs). On a consolidated basis, however, revenue jumped to Rs. 3,501.48 lakhs in Q3 (about double YoY) and Rs. 10,006.70 lakhs for 9M FY26 (up ~26%), though consolidated 9M PAT fell to Rs. 118.41 lakhs from Rs. 241.85 lakhs. The full-year FY25 audited consolidated results showed a loss of Rs. 610.75 lakhs with EPS of negative Rs. 0.35, a worrying number carried forward. The board also approved a Rs. 5 crore credit facility from Indus Finance, noted the in-principle BSE approval for a partly paid-up Rights Issue, and appointed Mr. K. Venkateswara Rao as the new CFO replacing the resigning Mr. Dhinakaran Rajagopal.
Mixed picture for shareholders: the standalone business is clearly shrinking but subsidiaries are driving top-line growth on a consolidated basis, while overall profitability is weakening and FY25 closed with a sizeable consolidated loss. A pending Rights Issue, Rs. 5 crore fresh debt, and a CFO change point to active fundraising and management transition, which could mean near-term dilution or balance-sheet pressure for existing shareholders.